Search hospitals > Minnesota > Duluth

CCOP - Duluth

Claim this profile
Duluth, Minnesota 55805
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Lymphoma
246 reported clinical trials
10 medical researchers
Photo of CCOP - Duluth in DuluthPhoto of CCOP - Duluth in Duluth

Summary

CCOP - Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cancer, Lymphoma and other specialties. CCOP - Duluth is involved with conducting 246 clinical trials across 168 conditions. There are 10 research doctors associated with this hospital, such as Rodolfo E. Bordoni, Amelia B Zelnak, MD, Sreekanth C. Reddy, and Gena H. Volas-Redd.

Area of expertise

1Breast Cancer
Global Leader
CCOP - Duluth has run 68 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
HER2 negative
2Lung Cancer
Global Leader
CCOP - Duluth has run 51 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at CCOP - Duluth

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cutaneous Melanoma
Melanoma
Cancer
Skin Cancer
ALK Gene Rearrangement
Recurrence
Lung Adenocarcinoma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Symptom Monitoring

for Young Women on Hormone Therapy

This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at CCOP - Duluth?
CCOP - Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cancer, Lymphoma and other specialties. CCOP - Duluth is involved with conducting 246 clinical trials across 168 conditions. There are 10 research doctors associated with this hospital, such as Rodolfo E. Bordoni, Amelia B Zelnak, MD, Sreekanth C. Reddy, and Gena H. Volas-Redd.